View from the Top: Cell and Gene Therapy Successes and Promise

In this excerpt from Nice Insight's Cell & Gene Therapy: 2023 Market Analysis, CDMO Pricing and Benchmarking report, we look back at the successes and failures of the cell and gene therapy sector in 2022 and the vista forward to the end of 2023.

    • Tags:

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Q: